Biotalys and Novozymes enter into a partnership to develop

Ghent, BELGIUM and Copenhagen, DENMARK, June 21, 2022 (GLOBE NEWSWIRE) — Biotalys (Euronext – BTLS), an agricultural technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, and Novozymes , a global leader in biotech solutions, today announced that the companies have entered into a partnership to expand the opportunities for Evoca™*, Biotalys’ first proprietary biocontrol.

The partnership envisions that Novozymes will use its expertise, intellectual property rights and know-how to explore additional avenues for the scale-up and production of Evoca’s bioactive protein, with the option of a possible commercial collaboration for a future generation of the product.

Evoca is an innovative protein-based biofungicide developed on Biotalys’ AGROBODY Foundry™ platform that helps control fungal diseases such as Botrytis and powdery mildew in fruits and vegetables. Demonstrating its strong performance through more than 600 independent, company-led field and greenhouse trials across multiple regions, pathogens, and crops, Evoca is on track to earn U.S. Environmental Protection Agency (EPA) approval. ) later this year. This should pave the way for regulatory evaluation of Biotalys’ portfolio of product candidates, which includes biofungicides, biobactericides and bio-insecticides based on the Biotalys AGROBODY Foundry technology platform.

“We are delighted to enter into this agreement with Novozymes, a global leader in biological solutions for agriculture and other industries,” shared Patrick Saddlesthe CEO of Biotalys. “With its extensive expertise in enzymes and protein fermentation technologies, Novozymes represents a strong partner to support Biotalys’ growth ambitions to provide producers around the world with an efficient and profitable future generation of Evoca. “

“We are excited to be able to add significant value to Biotalys’ technology through our industry-leading expertise in industrial fermentation to help Biotalys deliver cost-effective products to provide growers with new sustainable solutions to combat against pests, says Thomas Batchelor, vice president, Agricultural marketing and strategy of Novozymes. “We also see the Biotalys technology as potentially a good complement to our own portfolio of enzyme and microbial solutions as well as our existing commercial biocontrol portfolio.

Feasibility Sto study

As part of the agreement, Novozymes will initially explore whether it can scale and produce Evoca’s bioactive protein in additional production hosts to those currently used by Biotalys. Therefore, Novozymes will use its expertise, intellectual property and know-how and, as such, produce a future generation of Evoca that meets certain agreed success criteria. The outcome of this feasibility study can serve as a potential milestone for Biotalys and Novozymes to enter into development, supply and commercialization agreements for this future generation of Evoca.

* Evoca™: recording pendingration. This product is currently not registered for sale or use in the United Statesthe European Union, or elsewhere and is not offered for sale.

About Biotalys

Biotalys is an agricultural technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to control major crop pests and diseases across the entire value chain, from floor to plate. Biotalys was founded in 2013 as a spin-off from VIB (Flanders Institute for Biotechnology) and has been listed on Euronext Brussels since July 2021. The company is based in the biotech cluster of Ghent, Belgium. More information on www.biotalys.com.

For more information, please contact

Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: [email protected]

About Novozymes

Novozymes is the world leader in biological solutions. Together with our customers, partners and the global community, we improve industrial performance while conserving the planet’s resources and helping to build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, lower temperature washing, energy-efficient production, renewable fuels and many other benefits that we rely on today and in the future. We call it Rethinking Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • Turnover of DKK 15 billion • Over 30 sectors • Over 700 products

Media Relations

Lina Danstrup | Media Relations Manager | Telephone: +45 30 77 05 52 | [email protected]

Investor Relations
Tobias Bjorklund | Head of Investor Relations | Telephone: +45 30 77 86 82 | [email protected]

Important To remark

This announcement contains statements that are, or could be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “aim”, “believe”, “estimate”, “anticipate”, “expect”, “intend”, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plan’, ‘target’, ‘seek’, ‘would’ or ‘should’, and contain statements made by the company regarding the expected results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that none of these forward-looking statements offers any guarantee of future performance. The actual results of Biotalys may differ materially from those predicted by the forward-looking statements. Biotalys undertakes no obligation to release updates or adjustments to these forward-looking statements, except as required by law.

Comments are closed.